サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Fabry Disease Market Research Report – Global Forecast till 2023

ファブリー病市場調査レポート‐2023年までの世界予測

レポート概要

世界のファブリー病市場調査レポート:種類別(I型、II型)、診断&治療法別(血液検査、尿検査、画像診断、その他、治療法(酵素置き換えおよび遺伝子治療、抗けいれん薬、その他)))、エンドユーザー別∸2023年までの予測

市場シナリオ

世界のファブリー病市場は予測期間中に拡大が予想されます。2017年における市場価値は7億9,460万ドルと推定され、予測期間中に6.8%のCAGRで拡大する見込みです。ファブリー病は体細胞内にグロボトリアオシルセラミドが蓄積することによって起こる 希少な遺伝性疾患です。男性にもl女性にも起こり得ますが通常は男性の方が重症化しやすい疾患です。米国の国立衛生研究所(NIH)のデータによると、ファブリー病は男性4万人から6万人に1人の割合で発症します。

ファブリー病市場をけん引する要因の一つは長期に渡る研究開発活動です。2018年5がう30日にAmicus TherapeuticsがGalafoldカプセル123mgをファブリー病の確定診断を受けてamenable (素直に受け入れる)変異がある16歳以上の患者の治療薬として発売しました。また、Galafoldは日本でファブリー病に使用されている唯一の経口プレシジョン・メディシン(高精度医療)とも言われています。このほかにもファブリー病の治療のために多くの治療法について臨床試験が実施されています。例えば、ProtalixのPegunigalsidase alfaはフェーズ3臨床試験を実施中です。

そのほかにも、技術の進歩、医療インフラの整備、好ましい医療制度、開発途上国における財政支援政策などの様々な要因がこの市場の成長を加速させると予想されます。一方で、新興諸国や途上国におけるこの疾患に対する医師の認知不足、多様な症状、その他の併存疾患などが予測期間中における市場の成長を妨げる可能性があります。

レポート詳細

目次

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Macroeconomic Indicators
4.5 Pipeline Products

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Fabry Disease Market, by Type
6.1 Introduction
6.2 Type 1 Fabry Disease
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
6.3 Type 2 Fabry Disease
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023

Chapter 7. Global Fabry Disease Market, by Diagnosis & Treatment
7.1 Introduction
7.2 Diagnosis
7.2.1 Blood Test
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.2 Urine Test
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.3 Thyroid Test
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.4 Lung Function Test
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.5 Imaging
7.2.5.1 Electrocardiogram (EKG)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.5.2 Echocardiogram
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.5.3 Brain MRI
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.5.4 CT Scan
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.5.5 Others
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.6 Hearing and Eye Examination
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.2.7 Others
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3 Treatment
7.3.1 Enzyme Replacement Therapy
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.2 Gene Therapy
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.3 Pharmaceutical Formulations Containing Agalsidase Alfa
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.4 Analgesics
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.5 Anticonvulsants
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
7.3.7 Others
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023

Chapter 8. Global Fabry Disease Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
8.3 Diagnostic Centers
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
8.4 Research & Academic Institutes
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023
8.5 Others
Market Estimates & Forecast, by Region, 2018-2023
Market Estimates & Forecast, by Country, 2018-2023

Chapter 9. Global Fabry Disease Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa

Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies

Chapter 11. Company Profiles
11.1 AMGEN INC.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 AMICUS THERAPEUTICS, INC.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 BRISTOL-MYERS SQUIBB COMPANY
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 GlaxoSmithKline
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 IBio, Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Neuraltus Pharmaceuticals, Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Novartis AG
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 PFIZER INC.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Sanofi
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Shire
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Overview
11.11.2 Product Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Teva Pharmaceutical Industries Ltd
11.12.1 Overview
11.12.2 Product Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 AVROBIO, Inc.
11.13.1 Overview
11.13.2 Product Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.14 Idorsia Pharmaceuticals Ltd
11.14.1 Overview
11.14.2 Product Overview
11.14.3 Financials
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.15 Protalix
11.15.1 Overview
11.15.2 Product Overview
11.15.3 Financials
11.15.4 Key Developments
11.15.5 SWOT Analysis
11.16 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Fabry Disease Industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Global Fabry Disease Market Synopsis, 2018-2023
Table 2 Global Fabry Disease Market Estimates and Forecast, 2018-2023 (USD Million)
Table 3 Global Fabry Disease Market, by Region, 2018-2023 (USD Million)
Table 4 Global Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 5 Global Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 6 Global Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 7 North America: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 8 North America: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 9 North America: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 10 US: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 11 US: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 12 US: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 13 Canada: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 14 Canada: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 15 Canada: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 16 South America: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 17 South America: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 18 South America: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 19 Europe: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 20 Europe: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 21 Europe: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 22 Western Europe: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 23 Western Europe: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 24 Western Europe: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 25 Eastern Europe: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 26 Eastern Europe: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 27 Eastern Europe: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 28 Asia-Pacific: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 29 Asia-Pacific: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 30 Asia-Pacific: Fabry Disease Market, by End User, 2018-2023 (USD Million)
Table 31 Middle East & Africa: Fabry Disease Market, by Type, 2018-2023 (USD Million)
Table 32 Middle East & Africa: Fabry Disease Market, by Diagnosis & Treatment, 2018-2023 (USD Million)
Table 33 Middle East & Africa: Fabry Disease Market, by End User, 2018-2023 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure for Global Fabry Disease Market
Figure 3 Market Dynamics for Global Fabry Disease Market
Figure 4 Global Fabry Disease Market Share, by Type, 2017
Figure 5 Global Fabry Disease Market Share, by Diagnosis & Treatment, 2017
Figure 6 Global Fabry Disease Market Share, by End User, 2017
Figure 7 Global Fabry Disease Market Share, by Region, 2017
Figure 8 North America: Fabry Disease Market Share, by Country, 2017
Figure 9 Europe: Fabry Disease Market Share, by Country, 2017
Figure 10 Asia-Pacific: Fabry Disease Market Share, by Country, 2017
Figure 11 Middle East & Africa: Fabry Disease Market Share, by Country, 2017
Figure 12 Global Fabry Disease Market: Company Share Analysis, 2017 (%)
Figure 13 AMGEN INC.: Key Financials
Figure 14 AMGEN INC.: Segmental Revenue
Figure 15 AMGEN INC.: Geographical Revenue
Figure 16 AMICUS THERAPEUTICS, INC.: Key Financials
Figure 17 AMICUS THERAPEUTICS, INC.: Segmental Revenue
Figure 18 AMICUS THERAPEUTICS, INC.: Geographical Revenue
Figure 19 BRISTOL-MYERS SQUIBB COMPANY: Key Financials
Figure 20 BRISTOL-MYERS SQUIBB COMPANY: Segmental Revenue
Figure 21 BRISTOL-MYERS SQUIBB COMPANY: Geographical Revenue
Figure 22 GlaxoSmithKline: Key Financials
Figure 23 GlaxoSmithKline: Segmental Revenue
Figure 24 GlaxoSmithKline: Geographical Revenue
Figure 25 IBio, Inc.: Key Financials
Figure 26 IBio, Inc.: Segmental Revenue
Figure 27 IBio, Inc.: Geographical Revenue
Figure 28 Neuraltus Pharmaceuticals, Inc.: Key Financials
Figure 29 Neuraltus Pharmaceuticals, Inc.: Segmental Revenue
Figure 30 Neuraltus Pharmaceuticals, Inc.: Geographical Revenue
Figure 31 Novartis AG: Key Financials
Figure 32 Novartis AG: Segmental Revenue
Figure 33 Novartis AG: Geographical Revenue
Figure 34 PFIZER INC.: Key Financials
Figure 35 PFIZER INC.: Segmental Revenue
Figure 36 PFIZER INC.: Geographical Revenue
Figure 37 Sanofi: Key Financials
Figure 38 Sanofi: Segmental Revenue
Figure 39 Sanofi: Geographical Revenue
Figure 40 Shire: Key Financials
Figure 41 Shire: Segmental Revenue
Figure 42 Shire: Geographical Revenue
Figure 43 Takeda Pharmaceutical Company Limited: Key Financials
Figure 44 Takeda Pharmaceutical Company Limited: Segmental Revenue
Figure 45 Takeda Pharmaceutical Company Limited: Geographical Revenue
Figure 46 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 47 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 48 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 49 AVROBIO, Inc.: Key Financials
Figure 50 AVROBIO, Inc.: Segmental Revenue
Figure 51 AVROBIO, Inc.: Geographical Revenue
Figure 52 Idorsia Pharmaceuticals Ltd: Key Financials
Figure 53 Idorsia Pharmaceuticals Ltd: Segmental Revenue
Figure 54 Idorsia Pharmaceuticals Ltd: Geographical Revenue
Figure 55 Protalix: Key Financials
Figure 56 Protalix: Segmental Revenue
Figure 57 Protalix: Geographical Revenue

発刊日

2019/01

体裁

PDF / 100ページ

販売価格

4,450USD

発行

Market Research Future

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

医薬品原料・製剤 / 疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE